ALK-Abello A/S
CSE:ALK B
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
ALK-Abello A/S
CSE:ALK B
|
DK |
|
BTQ Technologies Corp
F:NG3
|
CA |
|
Nitto Denko Corp
F:ND50
|
JP |
|
G
|
Gamuda Bhd
KLSE:GAMUDA
|
MY |
|
G
|
Guan Chong Bhd
KLSE:GCB
|
MY |
|
I
|
Industrial and Commercial Bank of China Ltd
DUS:ICK
|
CN |
Intrinsic Value
Is ALK B undervalued or overvalued?
See the intrinsic value estimate for ALK-Abello A/S and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
ALK B looks overvalued.
But is it expensive by its own standards?
See how today’s valuation compares with ALK B’s past valuations and how the stock performed after similar periods.
Fundamental Analysis
What ALK-Abello A/S Does
ALK-Abello makes allergy treatment medicines and testing products. Its main business is allergy immunotherapy, which helps patients become less sensitive to things like pollen, dust mites, and animal allergens over time. It also sells allergy diagnostics used by doctors and clinics to identify what triggers a patient’s symptoms.
- Headquarters
- Denmark DK
- Employees
- 2 537
- IPO date
- Jan 1, 1961
Earnings Waterfall
ALK-Abello A/S
The intrinsic value for ALK-Abello A/S (ALK B) under the Base Case is hidden DKK.
Compared with the current market price of 237.2 DKK, the stock appears hidden.